Cited by 249Escherichia coli research studiesUrinary Tract Infections ManagementBacterial Infections and Vaccines

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Extraintestinal Pathogenic Escherichia coli , a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field

Open access

Poolman, Jan T., Wacker, Michael·2016·Journal of Infectious Diseases

Open this paper in CoChat — free account

Abstract

Extraintestinal pathogenic Escherichia coli (ExPEC) is the most common gram-negative bacterial pathogen in humans. ExPEC causes the vast majority of urinary tract infections (UTIs), is a leading cause of adult bacteremia, and is the second most common cause of neonatal meningitis. Increasing multidrug resistance among ExPEC strains constitutes a major obstacle to treatment and is implicated in increasing numbers of hospitalizations and deaths and increasing healthcare costs associated with ExPEC infections. An effective vaccine against ExPEC infection is urgently needed. The O antigen, a component of the surface lipopolysaccharide, has been identified as a promising vaccine target. With the availability of a novel bioconjugation technology it is expected that multivalent O antigen conjugate vaccines can be produced at industrial scale. Clinical proof of concept of a 4-valent O antigen conjugate vaccine is ongoing. An ExPEC vaccine effective against strains that are associated with major diseases and resistant to multiple drugs could be routinely delivered to individuals at risk of developing severe E. coli infection, such as elderly people, individuals undergoing abdominal surgery and prostatic biopsy procedures, and persons at risk of recurrent and/or complicated UTI.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/infdis/jiv429

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. Distribution of pathogens among isolates from 80 089 hospital admissions in 19 US hospitals between 2007 and 2010 [10]. Abbreviations: A. baumannii, Acinetobacter baumannii; E. coli, Escherichia coli; E. faecalis, Enterococcus faecalis; E. faecium, Enterococcus faecium; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas aeruginosa; S. aureus, Staphylococcus aureus.CC BY-NC-ND · PubMed Central

Figure 2. A, Incidence of Escherichia coli bacteremia, by age, in Auckland, New Zealand, between 2005 and 2011. The figure is reproduced from the article by Williamson et al [20]. B, rising numbers of E. coli bacteremia isolates reported to the European Antimicrobial Resistance Surveillance System between 2002 and 2008. Data are from the article by De Kraker et al [16]. Abbreviations: E. coli, Escherichia coli; S. aureus, Staphylococcus aureus; S. pneumoniae, Streptococcus pneumoniae.CC BY-NC-ND · PubMed Central

Figure 3. Escherichia coli O serotypes causing extraintestinal infections. Data are from the article by Orskov et al [41]. Abbreviation: UTIs, urinary tract infections.CC BY-NC-ND · PubMed Central

Figure 4. Process of in vivo bioconjugation, using recombinant Escherichia coli. Campylobacter oligosaccharyltransferase (PglB) transfers selected O polysaccharides (devoid of lipids) to the Pseudomonas aeruginosa exoprotein A (EPA) protein carrier present in the periplasm. Abbreviation: SEC, secretory pathway.CC BY-NC-ND · PubMed Central

Figure 5. Challenges to extraintestinal pathogenic Escherichia coli vaccine development. Individual challenges to vaccine development need to be surmounted to achieve successful technical development, appropriate strain selection, and demonstration of efficacy in the target population. Abbreviation: UTI, urinary tract infection.CC BY-NC-ND · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010
Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A. K., Patel, J. B., Srinivasan, A., Kallen, A. J., Limbago, B. M., Fridkin, S. K., & National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities (2012) · Infection Control and Hospital Epidemiology · doi:10.1086/668770 · Cited by 1,593
Urinary Tract Infection Syndromes
Foxman, B. (2013) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2013.09.003 · Cited by 1,336
Biosynthesis and Assembly of Capsular Polysaccharides in Escherichia coli
Whitfield, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142545 · Cited by 993
Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem
Russo, T. A., & Johnson, J. R. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(03)00049-2 · Cited by 801
The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection
Leibovici, Shraga, Drucker, Konigsberger, Samra, Pitlik, & Pitlik (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00379.x · Cited by 685
Escherichia coliSequence Type ST131 as the Major Cause of Serious Multidrug‐ResistantE. coliInfections in the United States
Johnson, J. R., Johnston, B., Clabots, C., Kuskowski, M. A., & Castanheira, M. (2010) · Clinical Infectious Diseases · doi:10.1086/653932 · Cited by 511
Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli
Feldman, M. F., Wacker, M., Hernandez, M., Hitchen, P. G., Marolda, C. L., Kowarik, M., Morris, H. R., Dell, A., Valvano, M. A., & Aebi, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500044102 · Cited by 442
Self-citation
The structures of Escherichia coli O-polysaccharide antigens
Stenutz, R., Weintraub, A., & Widmalm, G. (2006) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2006.00016.x · Cited by 410

Show all 48 references

Research works printed but not linked: 4

Vahlne, 1945, Serological typing of the colon bacteria, with special reference to the occurrence of B. coli in man under normal and pathological conditions, particularly in appendicitis, Acta Path Microbiol Scand, 62, 1
Sjostedt, 1946, Pathogenicity of certain serological types of B. coli: their mouse toxicity, hemolytic power, capacity for skin necrosis and resistance to phagocytosis and bactericidal faculties of human blood, Acta Path Microbiol Scand, 63, 1
Elixhauser A , Friedman B , Stranges E . Septicemia in U.S. Hospitals, 2009. Statistical brief 122. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Health Care Policy and Research, 2006. http://www.ncbi.nlm.nih.gov/books/NBK65391/ . Accessed 27 January 2015.
Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance Chaired by Jim O'Neill, 2014. http://www.his.org.uk/files/4514/1829/6668/AMR_Review_Paper_-_Tackling_a_crisis_for_the_health_and_wealth_of_nations_1.pdf . Accessed 26 December 2014.

Sorted by citations

Items 201–249 of 249

Research Progress on perinatal E. coli infection
Lin, Y. Y., Zhao, W., Xie, H., Lv, Z., Chen, S., Jin, H., & Wu, J. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1840209 · Cited by 1
Molecular Epidemiology and Drug Resistance of Extraintestinal Pathogenic Escherichia coli Bloodstream Isolates From Adults Worldwide (2011–2023)
de Been, M., Ritmahan, W., Zomer, A., Go, O. T., Aitabi, M., Oriol-Mathieu, V., Willame, C., Geurtsen, J., & Weerdenburg, E. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag453 · Cited by 1
Pathogenic potential of Escherichia coli from various sources in Port Harcourt, Rivers State, Nigeria
Otokunefor, K., & Nyema, P. (2019) · Journal of applied science and environmental management · doi:10.4314/jasem.v23i5.25 · Cited by 1
Genetic Background of β-Lactamase Genes in Extraintestinal Pathogenic Escherichia coli ST131 in Indonesia Based on Whole-Genome Sequencing (WGS) Sequences
Ilsan, N. A., Sipriyadi, S., Yunita, M., Nurfajriah, S., & Inggraini, M. (2022) · HAYATI Journal of Biosciences · doi:10.4308/hjb.29.4.540-548 · Cited by 1
Antimicrobial Resistance and Virulence of Escherichia coli in the Purview of Public Health Monitoring
Dhumal, P., Bajpai, S., Garge, N., Bhatt, A., Rampurwala, F., Sulaimani, N., Gaikwad, S. V., Roy, U., Mishra, M., & Deshmukh, R. A. (2022) · Pharmaceutical science. · doi:10.5772/intechopen.108299 · Cited by 1
Prevalence and In Vivo Assessment of Virulence in Shiga Toxin-Producing Escherichia coli Clinical Isolates from Greater Cairo Area
Elshimy, R. M., Hafez-Zedan, H., Elmorsy, T. H., & Khattab, R. A. (2023) · Microbial Drug Resistance · doi:10.1089/mdr.2022.0348 · Cited by 1
Characterization of Escherichia coli Isolated from Sows Presenting Purulent Vulvar Discharge
Poor, A. P., Moreno, L. Z., Monteiro, M. S., Matajira, C. E. C., Dutra, M. C., Leal, D. F., Silva, A. P., Gomes, V. T. M., de Souza, I. O., Araújo, K. M., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12010123 · Cited by 2
Risk of Invasive Escherichia coli (E. coli) Disease After Elective Urologic Procedures Among Older Adults in the United States
Neary, M. P., Catillon, M., Ahmad, N., Gauthier‐Loiselle, M., Geurtsen, J., Qu, A., Willame, C., Cloutier, M., Khoury, A. C. E., & Saade, E. A. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01096-w · Cited by 1
Les vaccins de demain
Lelièvre, J. (2019) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(19)30258-8 · Cited by 1
Diarrheagenic Escherichia coli signaling and interactions with host innate immunity and intestinal microbiota
Wang, G. (2017) · K-State Research Exchange (Kansas State University) · Cited by 1
Escape from antimicrobial CRISPR-Cas9 in E. coli ST131 depends on the genetic context of the target genePreprint
Morros-Bernaus, C., Westley, J., Wyrsch, E. R., Djordjevic, S. P., Zhang, L., Leonard, A., Gaze, W. H., Sünderhauf, D., & van Houte, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.04.668416 · Cited by 3
Extra-Intestinal Escherichia coli (Uropathogenic E. coli and Avian Pathogenic E. coli)
Leite, J. L., Rojas, T. C. G., Maluta, R. P., & da Silveira, W. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-45092-6_9
Engineering Probiotic Bacteria for Use as Antibiotic Alternatives
Forkus, B. (2018) · University of Minnesota Digital Conservancy (University of Minnesota)
LABORATORY ERRORS FOR IDENTIFICATION OF THE ESCHERICHIA COLI STRAINS OF THE SEROLOGICAL GROUPS O6 AND O25 AS ACUTE INTESTINAL INFECTIONS
Александровна, М. М., Николаевна, М. З., Smirnova, E. V., Semchenkova, L. I., Derevyanchenko, I. A., Sokol’nik, S. E., Zchirnova, L. Y., Kotova, N. K., Pelenko, T. V., Dudnikov, D. S., et al. (2020) · Russian Clinical Laboratory Diagnostics · doi:10.18821/0869-2084-2020-65-6-368-374
Contributions of the B. burgdorferi Vascular Adhesin BBK32 and Endothelial Surface Receptors to Mechanical Stabilization of Bacterial – Vascular Interactions
Ebady, R. (2020) · TSpace (University of Toronto)
Reconstitution and functional characterization of efflux pumps from Escherichia coli
Đorđević-Marquardt, S. (2021) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.61913
Faculty Opinions recommendation of One Health Genomic Surveillance of Escherichia coli Demonstrates Distinct Lineages and Mobile Genetic Elements in Isolates from Humans versus Livestock.
Bertrand, X. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734892638.793557651
FEATURES OF BIOFILM FORMATION OF SOME PATHOGENIC AND COMMENSAL ESCHERICHIA COLI ISOLATED FROM THE BODY OF DOGS AND CATS
BOIANOVSKIY, S., & Mazur, T. (2022) · Ukrainian journal of veterinary sciences · doi:10.31548/ujvs.13(1).2022.17-24
Progress toward the development of an effective vaccine for Extraintestinal pathogenic E. coli (ExPEC): The application of the multiple-protein subunits vaccine in different murine modelsPreprint
Xing, Y., Clark, J. R., Chang, J. D., Zulk, J. J., Chirman, D. M., Piedra, F.-A., Patras, K. A., & Maresso, A. W. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.31.543151
Extraintestinal Pathogenic Escherichia coli: Virulence Factors
Akdoğan, H., & Akpolat, N. (2023) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.54453/tmcd.2023.79037
Utilization of 5’-deoxy-nucleosides as Growth Substrates by Extraintestinal Pathogenic E. coli via the Dihydroxyacetone Phosphate ShuntPreprint
Huening, K. A., Groves, J. T., Wildenthal, J. A., Tabita, F. R., & North, J. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.10.552779
Additional file 1 of Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region
Hrovat, K., Molan, K., Seme, K., & Avguštin, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.24995540
The Prevalence and Susceptibility Patterns of Uropathogens in a Private Teaching Hospital: A Six Years Retrospective Study at GAMBY Teaching Hospital, Bahir Dar, EthiopiaPreprint
Gelaw, L. Y., Tessega, S. K., Afework, A., Adera, H., Teshome, A. T., Gizachew, B., Siraj, E. A., Setargew, S. T., Yayehrad, A. T., & Tebabal, A. T. (2024) · Research Square · doi:10.21203/rs.3.rs-4790331/v1
Comparative Genomics of Clinical Hybrid Escherichia Coli Strains in NorwayPreprint
Lindstedt, B.-A., Finton, M. D., Meisal, R., Porcellato, D., & Brandal, L. T. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4939657
Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60–85 years in a randomized, double-blind, phase 1 study
Haranaka, M., Momose, A., Nakayama, Y., Saito, Y., Spiessens, B., Davies, T. A., van den Dobbelsteen, G., POOLMAN, J. T., & Sarnecki, M. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.09.003
Self-citation
Escherichia and Shigella
Humphries, R. M., Faron, M. L., Dekker, J. P., Ledeboer, N. A., & Buchan, B. W. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0039
Escherichia and Shigella
Humphries, R. M., Faron, M. L., Dekker, J. P., Ledeboer, N. A., & Buchan, B. W. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0039 · Cited by 1
Importance and risks of enterobacteria for healthy development of newborn gut microbiota
Vinkler, J., Modráčková, N., Korček, P., Straňák, Z., & Bunešová, V. (2025) · Pediatrie pro praxi · doi:10.36290/ped.2025.006
Urogenital Vaccination: Addressing STIs and Beyond
Parveen, A., Singh, S., Tomar, D. S., Sharma, A., & Sharma, S. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324570125010009
Microbial Surface Glycan Probe Isolates Anti- l -Rhamnose Antibodies from Human Serum for Bacterial Detection
Milawati, H., Sheshova, M., Joo, J., & Lupoli, T. J. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00757
Additional file 1 of Clinical burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States
Hernandez-Pastor, L., Geurtsen, J., Baugh, B., Khoury, A. C. E., Kalu, N. U., Gauthier‐Loiselle, M., Bungay, R., Cloutier, M., Sarnecki, M., & Saade, E. (2023) · Figshare · doi:10.6084/m9.figshare.24013048
Additional file 4 of Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region
Hrovat, K., Molan, K., Seme, K., & Avguštin, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26667382
Additional file 2 of Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region
Hrovat, K., Molan, K., Seme, K., & Avguštin, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.24995589
Additional file 3 of Molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from lower respiratory tract samples between 2002 and 2019 in the Central Slovenia region
Hrovat, K., Molan, K., Seme, K., & Avguštin, J. A. (2024) · Figshare · doi:10.6084/m9.figshare.26667379
Engineering Escherichia coli to biosynthesize O-polysaccharide-derived recombinant glycoconjugate vaccines against pathogenic serotypes O8 and O9a
Li, Z., Ma, G., Liu, R. T., Wang, X., Wang, Y., Zhao, X., Meng, Q., Xie, L., Li, X., Liu, S., et al. (2026) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2026.125009
Harnessing pro-inflammatory and immunopathologic immune responses in urinary tract infections for vaccine development: it’s all about a balance
Periasamy, S., Lübbers, J., King, S. B. S., Hovingh, E. S., van der Fits, L., & van den Dobbelsteen, G. P. J. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1753331 · Cited by 2
Structural characterization reveals heterogeneity in the O-antigen polysaccharide of Escherichia coli O101 O-serogroup variants
Moran, A. B., Anish, C., Ravenscroft, N., Weerdenburg, E., Burghout, P., Grijpstra, J., Raghunath, M., Cramer, D. A. T., Torrente-López, A., Wuhrer, M., et al. (2026) · Carbohydrate Research · doi:10.1016/j.carres.2026.109888
Etude des amibes marines et de leurs interactions avec les vibrios pathogènes d’huître
Robino, E. (2019) · theses.fr (ABES) · doi:10.70675/2d93a513z2ba1z4764zb39dze601da384e5e
Analyse moléculaire et génomique des souches d'Escherichia coli : prévalence de la colibactine et résistance antimicrobienne
Azour, A. (2022) · theses.fr (ABES) · doi:10.70675/6b7eb9adz683fz4e80zb3efzb14ac932371a
Enterobacterales and Prognostic Nutritional Index in Hospitalised Bronchiectasis: Associations With Mechanical Ventilation and Long-Term Mortality
Sun, J., Wang, D., Liu, G., Li, D., Wang, X., He, X., Lv, W., Chen, X., Chen, J., Chen, X., et al. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.05.008
Genomic Characterization of Selected Multidrug-Resistant Escherichia coli Isolates from Healthy Dogs in Chile Reveals Diverse Lineages Including ST131
Sánchez, F., Galarce, N., Sáenz, L., & Lapierre, L. (2026) · Animals · doi:10.3390/ani16121769
Extraintestinal Pathogenic Escherichia coli (ExPEC)-like Infection Associated with Septicemia and Neurological Signs in Suckling Piglets: A Case Report
Gersemann, A., Reiner, G., & von Berg, S. (2026) · Veterinary Sciences · doi:10.3390/vetsci13070666
Glycan-decorated polymeric nanomedicine for the treatment of multidrug-resistant infections
Gao, R., Liu, H., Zhu, W., 戴世光, Żarnowski, R., Yi, K., Gu, L., Ye, M., Andes, D. R., Xie, R., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.07.019
Structured Co-Contamination Patterns of Foodborne Pathogens Across Raw Foods: Implications from a Decade-Long Public Health Surveillance Study in Gwangju, South Korea
Park, D. W., Yun, H. B., Jo, Y. G., Park, J. H., Kim, H., Lee, H. H., Cho, S., Lee, M. G., Jeong, H. J., Kang, I. S., et al. (2026) · Foodborne Pathogens and Disease · doi:10.1177/15353141261469385
Formulation Development of a Multivalent Bioconjugate ExPEC Vaccine Candidate: Linking Early Design to Late-Stage Stability and Manufacturability
Opacic, M., Labovitiadi, O., de Goede, P., & Capelle, M. A. H. (2026) · Vaccines · doi:10.3390/vaccines14080690
Development and validation of a high-throughput agglutination assay for O-serogrouping clinical Escherichia coli isolates
Shastry, R., Shang, W., Janssen, S., Tete, S., Domínguez, E. G., van den Dobbelsteen, G., Davies, T. A., & Morrow, B. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00991-26
Validation of electrochemiluminescent (ECL)-based immunoassay to determine the levels of antibodies against Escherichia coli O-lipopolysaccharide antigens
Kamdar, M., Shah, V., Janssen, S., Domínguez, E. G., Davies, T. A., & van den Dobbelsteen, G. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00863-26
Single-Cell Membrane-Permeabilization Kinetics Reveal Species-Specific Responses to Antimicrobial Photodynamic Treatment
Ahmed, O., Martínez, S. R., Khan, T., Paudyal, N., Amena, Y., Abouelyazid, M., & Durantini, A. M. (2026) · ACS Omega · doi:10.1021/acsomega.6c09003
Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace)
Bonten, M. J. M., Butler, C. C., Edwards, A., Gravenstein, S., Ikeda, H., Johansen, I. S., Lambregts, M. M. C., Matsumoto, T., Patterson, D. L., Rodríguez‐Baño, J., et al. (2026) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(26)00469-x
Self-citation

Authors: Poolman, J. T., & Wacker, M.
Affiliations: Janssen (Netherlands) (NL)
Corresponding author: Poolman, Jan T.
ORCID: Poolman, Jan T.
Venue: Journal of Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2015-09-02
Volume: 213
Issue: 1
Pages: 6-13
ISSN: 0022-1899 (ISSN-L)
1537-6613
DOI: 10.1093/infdis/jiv429
PMC: PMC4676548
OpenAlex: W2243816940
Cited by: 246
References: 48
Citations by year: 2026: 20 · 2025: 25 · 2024: 31 · 2023: 29 · 2022: 30 · 2021: 21 · 2020: 27 · 2019: 26 · 2018: 15 · 2017: 11 · 2016: 11
FWCI: 1.36
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
Locations: The Journal of Infectious Diseases (publishedVersion, cc-by-nc-nd)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
Health Sciences › Medicine › Urology › Urinary Tract Infections Management
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords: extraintestinal pathogenic Escherichia coli, vaccine development, lipopolysaccharide, urinary tract infection, bacteremia, neonatal meningitis, multidrug resistance, bioconjugation, multivalent vaccine, vaccine targets
MeSH terms: Escherichia coli, Escherichia coli Infections, Humans, Urinary Tract Infections, O Antigens, Escherichia coli Vaccines, Drug Resistance, Bacterial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Extraintestinal Pathogenic Escherichia coli , a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks